Abstract
The effect of the dopamine agonist, bromocriptine, and the dopamine antagonist, metoclopramide, on glucose tolerance was examined in maturity onset diabetics and normal subjects. After bromocriptine there was a lowered fasting blood glucose and improved glucose tolerance in the diabetics. The controls showed an initial improvement in glucose tolerance. A reduction in insulin levels and a marked fall in plasma prolactin was observed in all subjects. Growth hormone concentrations were low and unaffected in the diabetics, and there was an inconsistent rise in the normals. After metoclopramide there was some impairment in glucose tolerance in the normal subjects, but this was not significant in the diabetics. There was also a marked prolactin release in all subjects, but no significant effect on insulin or growth hormone. It is concluded that bromocriptine lowers the blood glucose and improves glucose tolerance in maturity onset diabetics. This action may be the result of the lowered prolactin which occurred without a concomitant rise in growth hormone.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Camanni F., Massara F., Belforte L., Molinatti G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. J Clin Endocrinol Metab. 1975 Mar;40(3):363–366. doi: 10.1210/jcem-40-3-363. [DOI] [PubMed] [Google Scholar]
- Del Pozo E., Del Re R. B., Varga L., Friesen H. The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine). J Clin Endocrinol Metab. 1972 Nov;35(5):768–771. doi: 10.1210/jcem-35-5-768. [DOI] [PubMed] [Google Scholar]
- Gnudi A., Lugari R., Cavazzini M. G. Variation of blood glucose and serum growth hormone, prolactin and insulin in subjects with insulin-dependent diabetes, after OGTT and pretreatment with 2-Br-alpha-ergocryptine. Acta Diabetol Lat. 1977 May-Aug;14(3-4):119–128. doi: 10.1007/BF02581399. [DOI] [PubMed] [Google Scholar]
- Landgraf R., Landraf-Leurs M. M., Weissmann A., Hörl R., von Werder K., Scriba P. C. Prolactin: a diabetogenic hormone. Diabetologia. 1977 Apr;13(2):99–104. doi: 10.1007/BF00745135. [DOI] [PubMed] [Google Scholar]
- Rozencweig M., Heuson J. C., Bila S., L'Hermite M., Robyn C. Effects of 2-Br-alpha-Ergocryptine, L-dopa and cyclic imides on serum prolactin in postmenopausal women. Eur J Cancer. 1973 Sep;9(9):657–664. doi: 10.1016/0014-2964(73)90008-x. [DOI] [PubMed] [Google Scholar]
- Thorner M. O., Chait A., Aitken M., Benker G., Bloom S. R., Mortimer C. H., Sanders P., Mason A. S., Besser G. M. Bromocriptine treatment of acromegaly. Br Med J. 1975 Feb 8;1(5953):299–303. doi: 10.1136/bmj.1.5953.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tolis G., Pinter E. J., Friesen H. G. The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man. Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):281–283. [PubMed] [Google Scholar]
- Woolf P. D., Lee L. A., Leebaw W., Thompson D., Lilavivathana U., Brodows R., Campbell R. Intracellular glucopenia causes prolactin release in man. J Clin Endocrinol Metab. 1977 Sep;45(3):377–383. doi: 10.1210/jcem-45-3-377. [DOI] [PubMed] [Google Scholar]